Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

The application of r-sHSA for treating chronic liver disease

A technology of analogs and substances, applied in the field of recombinant products of a functional gene, can solve the problems of insignificant curative effect, toxic and side effects, etc.

Inactive Publication Date: 2010-06-16
CHINA PHARM UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, although the drugs currently on the market for the treatment of liver fibrosis can restore liver function and prevent liver cirrhosis to a certain extent, the curative effect is not significant, and there are certain toxic and side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • The application of r-sHSA for treating chronic liver disease
  • The application of r-sHSA for treating chronic liver disease
  • The application of r-sHSA for treating chronic liver disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Protective effect of r-sHSA on carbon tetrachloride-induced liver fibrosis in rats

[0025] 1. Test drugs

[0026] Drug dosage: r-sHSA high dose group is 70μg / kg, the prepared concentration is 7μg / ml, i.p0.1ml / 10g; the middle dose group is 14μg / kg, prepared concentration is 1.4μg / ml, i.p0.1ml / 10g ; The low dose group is 2.8μg / kg, the preparation concentration is 0.28μg / ml, i.p0.1ml / 10g.

[0027] Experimental control: The blank control was injected intravenously with physiological saline in the same volume as the administration group.

[0028] Positive control: malotilate. Before use, add distilled water as needed to make a concentration of 0.83mg / ml, suspend evenly, and store at 4°C for later use.

[0029] 2. Experimental animals

[0030] SPF grade Wistar rats, all male, weighing 160-180g.

[0031] 3. Other experimental materials

[0032]Analytical pure carbon tetrachloride; phenobarbital sodium injection (0.1g / bottle); Luhua brand pure peanut oil; sodium chloride...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to biological medical technique, in particular to an application of a recombine product of a function gene of shark liver, as recombined liver simulate material (r-sHSA), which can be used to treat chronic liver disease, as liver fibrosis, chronic hepatitis or cirrhosis.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the medical application of a recombinant product of a functional gene derived from shark liver (recombinant liver-stimulating substance analogue, r-sHSA). Background technique [0002] Shark hepatic Stimulate Substance analogue (sHSA) is a new gene obtained from regenerated shark liver tissue for 24 hours, and its accession number in Genbank is AY099492. The amplification method, gene sequence and expression product (r-sHSA) sequence of sHSA have been publicly published by the inventor (Ye Boping. Cloning and sequence analysis of cDNA fragments of shark liver stimulating substance analogs [J]. China Natural Medicine, 2003, 1(2):5-9). [0003] Recombinant shark Hepatic Stimulate Substance Analogue (r-sHSA) is a recombinant protein obtained by expressing the sHSA gene in Escherichia coli by means of gene recombination, with a molecular weight of about 17,500 Da; at present, the inventor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/38A61K35/60A61P1/16A61P31/14A61P31/20
Inventor 叶波平王颖张伟金国虔丁选胜刘煜张玉斌吴梧桐
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com